Skip to main content
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. — Investor Relations & Filings

Ticker · WHWK ISIN · US00032Q1040 LEI · 549300G3U7TKW1M58L09 US Professional, scientific and technical activities
Open in API
Filings indexed 516 across all filing types
Latest filing 2020-06-26 Director's Dealing
Country US United States of America
Listing US WHWK

About Whitehawk Therapeutics, Inc.

https://ir.whitehawktx.com/

Whitehawk Therapeutics, Inc. is a preclinical-stage oncology company focused on developing advanced antibody-drug conjugate (ADC) therapies. The company applies next-wave platform technologies to established tumor biology to create treatments for difficult-to-treat cancers. Its portfolio features three ADC assets, which are engineered to overcome the limitations of first-generation predecessors through improved tumor targeting and clinical strategies. These assets are in-licensed from WuXi Biologics under an exclusive agreement for global development and commercialization.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2020-06-26 English
4 Filing
Director's Dealing
2020-06-26 English
4 Filing
Director's Dealing
2020-06-26 English
8-K Filing
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 24, 2020. It reports the results of the Annual Meeting of Stockholders, including voting outcomes on director elections, a reverse stock split proposal, and appointment of the independent auditor. It also includes a notification about Nasdaq compliance and a press release about a clinical trial initiation. The key content is the submission of matters to a vote of security holders, which is typical for a Declaration of Voting Results filing. The document is about the voting results from the Annual Meeting, not the meeting materials themselves or the full annual report. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (5705 characters) supports it being a full report of voting results rather than a brief announcement or proxy solicitation.
2020-06-25 English
8-K Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 27, 2020. It includes a corporate presentation (Exhibit 99.2) intended for investor meetings and a press release about participation in a COVID-19 study (Exhibit 99.1). The text explicitly states the corporate presentation is furnished under Item 7.01 Regulation FD Disclosure, which is typically used to share investor presentations or similar materials. The document length is 4357 characters, which is relatively short and mainly announces the availability of the corporate presentation and press release rather than containing detailed financial data or full reports. Therefore, this filing is best classified as an Investor Presentation (IP) type filing, as it primarily provides a presentation for investors focusing on financials, strategy, and market position.
2020-05-28 English
SC 13D/A Filing
Major Shareholding Notification
2020-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.